Meloxicam is an enolcarboxamide with preferential COX-2 inhibitory activity ... with placebo or other nonsteroidal anti-inflammatory drugs (NSAIDs). Overall, the efficacy of meloxicam was ...

Elucidation of COX-2 regulatory pathways will lead to the development of new anti-inflammatory agents. It will be a major challenge, however, to pharmacologically modulate COX-2 function in ...

NSAIDs-- or nonsteroidal anti-inflammatory drugs -- are among the ... They block the effects of special enzymes -- specifically Cox-1 and Cox-2 enzymes. These enzymes play a key role in making ...

Gastrointestinal dysmotility commonly follows thermal injuries, such as burns. This study aimed to investigate the effects and mechanisms of electroacupuncture (EA) on burn-induced gastric dysmotility ...

Meloxicam reaches maximum plasma concentration (Cmax) at 9-11 hours after a 30mg dose and 2.5-7 hours after a 15mg dose. Meloxicam is strongly bound to plasma proteins (99.5%). Meloxicam displays ...